Vinpotsetin-AKOS

General characteristics. Structure:

Active agent: a Vinpocetine - 5 mg. excipients: lactose (sugar milk), potato starch, talc, magnesium stearate, magnesium carbonate.

Pharmacological properties:

Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissue. Increases resistance of neurons to a hypoxia; strengthens glucose transport to a brain, through a blood-brain barrier; transfers process of disintegration of glucose to energetically more economical, aerobic way; selectively blocks Sa 2+ - dependent phosphodiesterase; increases levels of adenosinemonophosphate (AMF), a cyclic guanozinmonofosfat (tsGMF) and adenosinetriphosphate (ATP) of a brain. Strengthens exchange of noradrenaline and serotonin of a brain; stimulates the ascending branch of noradrenergichesky system, has antioxidant effect. Reduces aggregation of thrombocytes and the increased viscosity of blood; increases the deforming ability of erythrocytes and blocks utilization by adenosine erythrocytes; promotes increase in return of oxygen erythrocytes. Increases a cerebral blood stream; reduces resistance of vessels of a brain without essential change of indicators of system blood circulation. Does not render effect of "burglarizing" and strengthens blood supply, first of all, in ischemic sites of a brain. Gets through a placental barrier.

Pharmacokinetics. It is quickly soaked up. Time of achievement of the maximum concentration in a blood plasma - 1 hour. Absorption happens, mainly, in proximal departments of a zheludchno-intestinal path. When passing through a wall of intestines is not exposed to metabolism. The maximum concentration in fabrics is noted in 2-4 h after intake. Communication with proteins - 66%, bioavailability at intake - 7%. The clearance of 66,7 l/h, exceeds the plasma volume of a liver (50 l/h) that demonstrates extrahepatic metabolism. At repeated receptions the kinetics has linear character. An elimination half-life at the person of 4,83±1,29 h. It is removed by kidneys and through intestines in the ratio 3:2.

Indications to use:

Reduction of expressiveness of neurologic and mental symptoms at various forms of insufficiency of cerebral circulation (including a recovery stage of an ischemic or hemorrhagic stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; atherosclerosis of vessels of a brain; posttraumatic and hypertensive encephalopathy);
- chronic vascular diseases of a choroid and retina of an eye;
- decrease in hearing of perceptual type, Menyer's disease, idiopathic sonitus.

Route of administration and doses:

Inside, after food, 3 times a day. The initial daily dose makes 15 mg. Maximum daily dose of 30 mg. Duration of a course of treatment up to 3 months, At diseases of kidneys or a liver drug is appointed in a usual dose.
Before cancellation the dose should be reduced gradually.

Features of use:

With care apply inside at arrhythmia, stenocardia, at the unstable ABP and the lowered vascular tone. Parenterally, as a rule, apply in acute cases before improvement of a clinical picture, then pass to intake. At chronic diseases the Vinpocetine is accepted inside. At a hemorrhagic cerebral stroke parenteral administration of a Vinpocetine is allowed only after reduction of the acute phenomena (usually 5-7 days).

Side effects:

From cardiovascular system: passing arterial hypertension, tachycardia; seldom - premature ventricular contraction, increase in time of excitement of ventricles.

Interaction with other medicines:

At simultaneous use with warfarin it is reported about small reduction of anticoagulating effect of warfarin.

At simultaneous parenteral use of a Vinpocetine and heparin increase in risk of bleedings is possible.

Contraindications:

Acute phase of a hemorrhagic stroke, the expressed coronary heart disease, the expressed arrhythmias, hypersensitivity to any of drug components.
- pregnancy (perhaps placental bleeding and spontaneous abortions probably as a result of strengthening of placental blood supply).
- the lactation period (at use of drug it is necessary to stop breastfeeding).
- children up to 18 years (in connection with insufficiency of data).
 
Use at pregnancy is not specified.

Storage conditions:

In the place protected from light at a temperature not above 25 °C. To store in the places unavailable to children. 
Period of validity of 5 years. Not to use after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

10 pieces - planimetric strip packagings (5) - packs cardboard.